CORRIGENDUM

Loci influencing blood pressure identified using a cardiovascular gene-centric array

Santhi K. Ganesh, Vinicius Tragante, Wei Guo, Yiran Guo, Matthew B. Lanktree, Erin N. Smith, Toby Johnson, Berta Almoguera Castillo, John Barnard, Jens Baumert, Yen-Pei Christy Chang, Clara C. Elbers, Martin Farrall, Mary E. Fischer, Nora Franceschini, Tom R. Gaunt, Johannes M.I.H. Gho, Christian Gieger, Yan Gong, Aaron Isaacs, Marcus E. Kleber, Irene Mateo Leach, Caitrin W. McDonough, Matthijs F.L. Meijs, Olle Mellander, Cliona M. Molony, Ilja M. Nolte, Sandosh Padmanabhan, Tom S. Price, Ramakrishnan Rajagopalan, Jonathan Shaffer, Sonia Shah, Haiqing Shen, Nicole Soranzo, Peter J. van der Most, Erik P.A. Van Iperen, Jessica Van Setten, Judith M. Vonk, Li Zhang, Amber L. Beitelshes, Gerald S. Berenson, Deepak L. Bhatt, Jolanda M.A. Boer, Eric Boerwinkle, Ben Burkley, Amber Burt, Aravinda Chakravarti, Wei Chen, Rhonda M. Cooper-DeHoff, Sean P. Curtis, Albert Dreisbach, David Duggan, Georg B. Ehret, Richard R. Fabsitz, Myriam Fornage, Ervin Fox, Clement E. Furlong, Ron T. Gansevoort, Marten H. Hofker, G. Kees Hovingh, Susan A. Kirkland, Kandice Kottke-Marchant, Abdullah Kutlar, Andrea Z. LaCroix, Taimour Y. Langaee, Yun R. Li, Honghuang Lin, Kiang Liu, Steffi Maiwald, Rainer Malik, CARDIOGRAM METASTROKE, Gurunathan Murugesan, Christopher Newton-Cheh, Jeffery R. O'Connell, N. Charlotte Onland-Moret, Willem H. Ouwehand, Walter Palmas, Brenda W. Penninx, Carl J. Pepine, Mary Pettinger, Joseph F. Polak, Vasan S. Ramachandran, Jane Ranchalis, Susan Redline, Paul M. Ridker, Lynda M. Rose, Hubert Scharnag, Nicholas J. Schork, Daichi Shimbo, Alan R. Shuldiner, Sathanur R. Srinivasan, Ronald P. Stolk, Herman A. Taylor, Barbara Thorand, Mieke D. Trip, Cornelia M. van Duijn, W. Monique Verschuren, Cisca Wijmenga, Bernhard R. Winkelmann, Sharon Wyatt, J. Hunter Young, Bernhard O. Boehm, Mark J. Caulfield, Daniel I. Chasman, Karina W. Davidson, Pieter A. Doevendans, Garret A. FitzGerald, John G. Gums, Hakon Hakonarson, Hans L. Hillege, Thomas Illig, Gail P. Jarvik, Julie A. Johnson, John J.P. Kastelein, Wolfgang Koenig, LifeLines Cohort Study, Winfried März, Braxton D. Mitchell, Sarah S. Murray, Albertine J. Oldehinkel, Daniel J. Rader, Muredach P. Reilly, Alex P. Reiner, Eric E. Schadt, Roy L. Silverstein, Harold Snieder, Alice V. Stanton, André G. Uitterlinden, Pim van der Harst, Yvonne T. van der Schouw, Nilesh J. Samani, Andrew D. Johnson, Patricia B. Munroe, Paul I.W. de Bakker, Xiaofeng Zhu, Daniel Levy, Brendan J. Keating and Folkert W. Asselbergs

Human Molecular Genetics 2013; **22**:8; pp. 1663–1678; doi:10.1093/hmg/ddt555

An author's name was incorrectly shown as Jessica A. Van Setten when it should have been Jessica Van Setten as shown above. Also, in the Replication Cohorts section of Table 1, we have noticed some errors in the medication column. The corrected Table is shown here.

The authors apologise for these mistakes.

Table 1: Clinical Characteristics

Discovery Cohorts	Age	Female/Male	SBP	DBP	MAP	PP	BMI	Taking anti-hypertensive medication
AMC-PAS	42.9 ± 5.3	180/563	128.6 ± 17.9	79.9 ± 10.7	96.1 ± 12.1	48.8 ± 13.1	26.9 ± 4.1	33.2%
Amish	47.6 ± 15.0	713/691	121.9 ± 16.5	75.3 ± 9.4	90.8 ± 10.8	46.6 ± 12.2	27.3 ± 5.0	16.4%
ARIC	54.2 ± 5.7	5124/4453	118.3 ± 17	71.5 ± 10	87.1 ± 11.3	46.7 ± 12.7	26.9 ± 4.9	25.1%
BHS	22.5 ± 4.4	291/228	111.5 ± 10.2	71.8 ± 8.5	85 ± 8.3	39.7 ± 8	24.7 ± 6.1	2.7%
CARDIA	40.6 ± 4.1	703/623	102.2 ± 30.5	71.9 ± 11.2	84.5 ± 11.4	37.7 ± 8.8	26.9 ± 6.4	3.7%
CCCS	64.2 ± 9.7	555/1402	136.94 ± 19.04	78.33 ± 10.61	156.48 ± 23.57	58.61 ± 15.69	29.2 (4.8)/29.8 (6.5)	88.7%
CFS	40.9 ± 19.9	302/252	121.1 ± 16.6	71.8 ± 11.7	88.2 ± 12.2	49.3 ± 12.4	30.1 ± 8.8	8.8%
CHS	72.6 ± 6.3	2208/1722	135.3 ± 21.5	69.9 ± 11.6	91.7 ± 12.9	65.4 ± 18.6	26.3 ± 4.8	39.7%
CLEAR	67.8 ± 9.6	0/1365	151.4 ± 22.4	82.2 ± 12.3	105.3 ± 13.8	69.2 ± 18.4	28.1 ± 5.0	67.0%
EPIC_NL	54.06 ± 10.11	4057/1137	133.13 ± 21.22	80.46 ± 10.93	97.98 ± 13.20	52.65 ± 15.68	26.77 ± 4.45	0%
FHS	40.9 ± 9.1	3775/3134	118.6 ± 14.3	76.4 ± 9.8	90.5 ± 10.6	42.2 ± 9.4	26.1 ± 5	5.5%
GIRaFH	44.5 ± 11.7	882/812	134.9 ± 19.2	82.0 ± 10.5	99.7 ± 12.3	52.9 ± 14.4	25.1 ± 3.5	9.3%
GQ2	65.5 ± 10.5	385/93	130.51 ± 22.40	72.71 ± 12.89	149.78 ± 27.66	57.81 ± 18.47	29.7 (7.7)/29.5 (6.3)	76.2%
INVEST	69.4 ± 9.5	467/580	160.8 ± 17.4	90.6 ± 10.1	114.0 ± 10.6	70.1 ± 15.9	29.0 (4.7)/28.4 (6.2)	82.6%
LURIC	58.1 ± 8.6	558/1480	151.2 ± 24.4	89.8 ± 12.1	110.3 ± 15.0	61.4 ± 17.6	27.7 ± 4.2	85.6%
MEDAL	62.9 ± 9.0	1178/2820	136.8 ± 16.0	81.7 ± 9.6	94.9 ± 8.6	52.9 ± 11.5	30.5 ± 6.3	1.4%
MESA	62.7 ± 10.3	1199/1097	123.5 ± 20.8	70.1 ± 10.2	87.9 ± 12.3	53.4 ± 16.7	27.8 ± 5.1	33.3%
MONICA/KORA F3	57.6 ± 8.1	755/649	131.8 ± 19.4	83.3 ± 10.3	99.5 ± 12.6	48.5 ± 13.2	27.8 ± 4.5	30.1%
MONICA/KORA S12	51.8 ± 9.9	431/549	133.6 ± 19.1	81.5 ± 11.1	98.8 ± 12.5	52.1 ± 14.6	27.2 ± 4.0	16.6%
NSHS95	49.4 ± 18.4	857/899	126.6 ± 17.7	76.7 ± 11.6	93.3 ± 11.8	49.9 ± 15.8	27.1 ± 5.5	N/A
PEAR	50.1 ± 9.4	194/244	151.8 ± 12.4	98.0 ± 5.7	115.9 ± 6.9	53.7 ± 10.8	[30.3 (4.4)/30.4 (6.1)]	0%
PennCAC	56.0 ± 8.0	631/1145	132 ± 23.2	72.4 ± 11.2	52.6 ± 12.6	59.5 ± 19.7	29.8 ± 5.9	N/A
PennCath	52.0 ± 9.0	739/1386	127 ± 15.1	76.7 ± 9.5	62.9 ± 10.5	51.9 ± 12.3	30.1 ± 5.9	32.8%
SMART	59.36 ± 12.25	206/299	158.64 ± 18.57	94.76 ± 11.80	116.06 ± 12.87	63.88 ± 13.78	27.35 ± 4.62	39.4%
WHI	68.0 ± 6.6	7606/0	133.0 ± 18.8	75.0 ± 9.7	94.3 ± 11.0	58.0 ± 16.2	28.3 (6.2)	33.3%
Replication Cohorts	Age	Female/Male	SBP	DBP	MAP	PP	BMI	Taking anti-hypertensive medication
AIBIII	52.8 (9.2)	249/209	119.9 (13.7)	75.4 (7.6)	90.2 (8.8)	44.5 (10.3)	25.7 (3.6)	0.0%
ASCOT	63 (8.1)	224/1015	161.4 (17.8)	92.9 (9.9)	115.7 (10.6)	68.5 (16.1)	29.1 (4.6)	89.2%
BRIGHT (controls)	58.7 (8.9)	1088/647	123 (10.5)	76.4 (7.2)	91.9 (7.5)	46.7 (8.3)	25.3 (3.3)	0.0%
BRIGHT (cases)	58 (10.3)	1144/775	154.3 (21.1)	93.9 (11.3)	114 (13.3)	60.4 (15.7)	58 (10.3)	92.5%
BWHHS	68.85 (5.51)	3373/0	146.53 (26.59)	79.16 (12.85)	102 (15)	67.6 (19)	27.25 (5.95)	30.2%
GRAPHIC	39.30 (14.50)	1004/1020	127.09 (17.84)	79.12 (10.96)	95.1 (12.5)	48 (11.9)	26.11 (4.61)	6.7%
LIFELINES	47.3 ± 11.2	4640/3483	127.9 ± 15.7	75.1 ± 9.1	52.7 ± 11.8	92.7 ± 10.3	26.3 ± 4.3	15.5%
MDC	57.8 (5.9)	1074/772	115.6 (5.8)	73.6 (5.3)	87.6 (4.7)	42 (6)	24.3 (3.3)	0.0%
NBS	41.36 (12.37)	1183/1169	N/A	N/A	N/A	N/A	N/A	N/A
NESDA	41.5 ± 12.7	1166 / 551	135.3 ± 20.2	81.7 ± 11.8	99.6 ± 13.9	53.6 ± 12.7	25.5 ± 4.9	12.8%
NORDIL	56 (4)	979/940	177.3 (14.6)	105.9 (5.5)	129.7 (7.1)	71.5 (13.9)	28.3 (4.6)	0.0%
PREVEND	49.6 ± 12.5	1752/1869	129.1 ± 19.9	74.1 ± 9.9	54.9 ± 13.9	92.4 ± 12.5	26.1 ± 4.3	14.2%
Procardis	59.34 (9.93)	1634/1564	130.75 (17.11)	79.63 (10.03)	96.7 (11.2)	51.1 (13.4)	26.81 (4.37)	19.3%
Rotterdam Study	69.4 (9.1)	3327 / 2327	144.1 (24.2)	76.9 (12.6)	99.3 (15.0)	67.1 (18.5)	26.3 (3.7)	32.5%
TRAILS clinical cohort	15.8 ± 0.6	97 / 217	119.1 ± 12.6	61.0 ± 6.6	80.4 ± 7.3	58.1 ± 11.4	21.5 ± 3.6	N/A
TRAILS population cohort	16.2 ± 0.7	693 / 642	118.1 ± 12.4	61.1 ± 6.9	80.1 ± 7.4	57.7 ± 10.6	21.2 ± 3.2	N/A
WGHS	54.2 ± 7.1	22625/0	125.5 ± 16.4	78.0 ± 10.7	93.8 ± 11.9	47.6 ± 10.4	25.9 ± 5.0	12.9%
WHII	60.83 (6.0)	1845/3210	128.1 (16.7)	74.6 (10.5)	92.4 (11.8)	53.5 (11.2)	26.7 (4.3)	22.8%

Mean ± Standard deviation is given for each phenotype, except % where indicated.